Abiomed seeks HDE approval
This article was originally published in The Gray Sheet
Executive Summary
Danvers, Mass. firm submits humanitarian device exemption application for its AbioCor implantable replacement heart Sept. 1 and anticipates HDE approval by the end of its fiscal year in March 2005 (1"The Gray Sheet" April 19, 2004, p. 23). Abiomed has enrolled 14 of 15 patients for its clinical trial, the firm also notes Sept. 8...
You may also be interested in...
Abiomed’s HDE application
AbioCor humanitarian device exemption is "on track and proceeding as expected," despite the early wear-out of a bearing that resulted in the death of a patient implanted with the artificial heart, CEO Michael Minogue says Oct. 21. According to the firm's investigation, the premature bearing wear-out was due to a combination of the patient's cardiovascular anatomy and the limited range of a shutter to control blood flow, which placed excessive loads on the system. The firm has taken immediate actions to prevent recurrence, including changing the manufacturing selection process of the shutter and guidelines for device and patient management, Abiomed reports. Under the Sept. 1 HDE, the firm is seeking an AbioCor indication to treat a defined subset of irreversible end-stage heart failure patients (1"The Gray Sheet" Sept. 13, 2004, In Brief)...
Abiomed To Upgrade IT Applications Of AB5000 Circulatory Support System
Abiomed President and CEO Michael Minogue says the IT experience he gained in 11 years at GE Medical Systems will help to differentiate the firm's circulatory support devices from their competitors
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.